S80246 |
Sivelestat |
源葉(MedMol) | 98% |
- 提示:詳情請下載說明書。
- 產品描述: Sivelestat is a potent and selective inhibitor of neutrophil elastase with IC50 of 44 nM.
- 靶點: SARS-CoV;Serine Protease;SARS-CoV;SerineProtease
- 體內研究:
Administration of sivelestat attenuates pulmonary fibrosis after acute lung injury in mice. Sivelestat could attenuate sepsis-related kidney injury in rats. It blocks GAPDH/Siah1 which is a novel signaling pathway during the progression of spinal cord injury.
- 細胞實驗: TMK-1 Gastric carcinoma cells are seeded into 96-well culture plates (5 ×103 cells/well) in RPMI containing 7% FBS, 2.0 mM L-glutamine, and 1% nonessential amino acids. Following 24-h incubation in RPMI-1640 medium with 5% FBS, the cells are incubated for 24, 48 or 72 h at 37°C in a humidified atmosphere of 5% CO2 with varied concentrations (0.1–1.0 μg/mL) of NE, or with varied concentrations (0.1–1000 μg/mL) of sivelestat or with concentrations (10 and 100 ng/mL) of anti-TGF-α antibody in the presence of 1 μg/mL NE. After incubation, 10 μL of MTT solution (5 mg/mL) is added to each well and the plates are then incubated for 3 h at 37°C. The growth medium is then replaced with 150 μL of dimethyl sulfoxide (Wako) per well and the absorbance at 540 nm is measured.
- 動物實驗: Animal Models: Male Sprague-Dawley rats. Formulation: Saline. Dosages: 50 or 100 mg/kg. Administration: i.p.
- 參考文獻:
1.Li G, et al. Int J Mol Med. 2016, 38(3):767-75. 2.Huo J, et al. Neuroscience. 2016, 330:171-180. 3.Hagiwara S, et al. Inflamm Res. 2009, 58(4):198-203. 4.Wada Y, et al. Cancer Science. 2006, 97(10):1037-1043. 5.Araki Y, et al. Dig Dis Sci. 2011, 56(6):1672-81.
- 溶解性: Ethanol:80 mg/mL (184.1 mM) H2O:<1 mg/mL DMSO:80 mg/mL (184.1 mM)
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.302 ml 11.508 ml 23.017 ml 5 mM 0.46 ml 2.302 ml 4.603 ml 10 mM 0.23 ml 1.151 ml 2.302 ml 50 mM 0.046 ml 0.23 ml 0.46 ml
- 注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
輸入產品批號:
本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系,公式為:
質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)